Showing results (61-70 of 65) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Blood|September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myelomaAurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.Blood|October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaThomas Dejoie, Jill Corre, Helene Caillon, et al.The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.Pageof 7